IMMU-132 for Patients with Stage IV Triple Negative Breast Cancer

A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients with Epithelial Cancer

November 22, 2017

  • Clinical Trial Information

    Trial Contact: Morales, Leticia; Pelley, Jennifer; Walton, Sherri; Jobson, Gillian S

    Trial Phone: 321.841.6696 ; 321.841.4348 ; 321.841.1907 ; 321.841.2285

  • IRB No: 13.029.03

    Protocol Abbrev: IMMU-132-01

    Principal Investigator: Rebecca L. Moroose, MD

    Sub Investigators: Hajdenberg, Julio MD; Johnson, Tirrell MD; Kayaleh, Omar MD; Landau, Daniel MD; Moroose, Rebecca MD; Rostorfer, Regan MD; Shah, Nikita MD; Tseng, Jennifer MD; Cuesta, Ana MD; Maddipatla, Sreeram MD

    Phase: Drug: Phase I

    Age Group: Adult

    Secondary Protocol No: IMMU-132-01

    Treatment: Medication

    Applicable Disease Sites: Multiple

    Therapies Involved: Drug: IMMU-132

    ClinicalTrials.gov ID: NCT01631552

  • Objective

    The objective is to evaluate the safety and tolerability of IMMU-132 in previously treated patients with advanced epithelial cancer.

  • Key Eligibility

    Must have measurable disease.